Xianju Pharmaceutical announced that the company previously submitted an ANDA registration application for progesterone vaginal tablets to the US Food and Drug Administration, and recently received a notice of acceptance of the US FDA registration application. The specification is 100 mg, application number 221303. This acceptance marks that the product has entered a substantial stage of reporting to the US FDA, and subsequent procedures such as review, approval, and on-site inspection will be carried out.

Xianju Pharmaceutical announced that the company previously submitted an ANDA registration application for progesterone vaginal tablets to the US Food and Drug Administration, and recently received a notice of acceptance of the US FDA registration application. The specification is 100 mg, application number 221303. This acceptance marks that the product has entered a substantial stage of reporting to the US FDA, and subsequent procedures such as review, approval, and on-site inspection will be carried out.